Evaluating Trastuzumab in the treatment of HER2 positive breast cancer

被引：4

作者：

Jaques, Ryan ^{[1
]}

Xu, Sam ^{[1
]}

Matsakas, Antonios ^{[1
]}

机构：

[1] Univ Hull, Ctr Atherothrombot & Metab Dis, Hull York Med Sch, Kingston Upon Hull, N Humberside, England

来源：

HISTOLOGY AND HISTOPATHOLOGY | 2020年 / 35卷 / 10期

关键词：

Breast cancer; Herceptin; Trastuzumab; Immunotherapy; HER2; EPIDERMAL-GROWTH-FACTOR; LAPATINIB PLUS CAPECITABINE; QUALITY-OF-LIFE; PHASE-II TRIAL; ADJUVANT TRASTUZUMAB; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; AEROBIC EXERCISE; RANDOMIZED-TRIAL; OPEN-LABEL;

D O I：

10.14670/HH-18-221

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The transmembrane oncoprotein HER2 is encoded by ERBB2 gene and overexpressed in around 20% of invasive breast cancers. It can be specifically targeted by Trastuzumab (Herceptine), a humanised IgG1 antibody. Trastuzumab has been regarded as one of the most effective therapeutic drugs targeted to HER2 positive cancers. However, there are drawbacks, notably cardiotoxicity and resistance, which have raised awareness in clinical use. Therefore, understanding the mechanism of action is vital to establish improved therapeutic strategies. Here we evaluate Trastuzumab application in the treatment of HER2 positive breast cancer, focusing on its mechanistic actions and clinical effectiveness. Alternative therapies targeting the HER2 receptor and its downstream anomalies will also be discussed, as these could highlight further targets that could be key to improving clinical outcomes.

引用

页码：1059 / 1075

页数：17

共 112 条

[31] Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial [J].

Gianni, Luca ;

Dafni, Urania ;

Gelber, Richard D. ;

Azambuja, Evandro ;

Muehlbauer, Susanne ;

Goldhirsch, Aron ;

Untch, Michael ;

Smith, Ian ;

Baselga, Jose ;

Jackisch, Christian ;

Cameron, David ;

Mano, Max ;

Pedrini, Jose Luiz ;

Veronesi, Andrea ;

Mendiola, Cesar ;

Pluzanska, Anna ;

Semiglazov, Vladimir ;

Vrdoljak, Eduard ;

Eckart, Michael J. ;

Shen, Zhenzhou ;

Skiadopoulos, George ;

Procter, Marion ;

Pritchard, Kathleen I. ;

Piccart-Gebhart, Martine J. ;

Bell, Richard .

LANCET ONCOLOGY, 2011, 12 (03) :236-244

[32] Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J].

Gianni, Luca ;

Eiermann, Wolfgang ;

Semiglazov, Vladimir ;

Manikhas, Alexey ;

Lluch, Ana ;

Tjulandin, Sergey ;

Zambetti, Milvia ;

Vazquez, Federico ;

Byakhow, Mikhail ;

Lichinitser, Mikhail ;

Angel Climent, Miguel ;

Ciruelos, Eva ;

Ojeda, Belen ;

Mansutti, Mauro ;

Bozhok, Alla ;

Baronio, Roberta ;

Feyereislova, Andrea ;

Barton, Claire ;

Valagussa, Pinuccia ;

Baselga, Jose .

LANCET, 2010, 375 (9712) :377-384

[33] Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial [J].

Goss, Paul E. ;

Smith, Ian E. ;

O'Shaughnessy, Joyce ;

Ejlertsen, Bent ;

Kaufmann, Manfred ;

Boyle, Frances ;

Buzdar, Aman U. ;

Fumoleau, Pierre ;

Gradishar, William ;

Martin, Miguel ;

Moy, Beverly ;

Piccart-Gebhart, Martine ;

Pritchard, Kathleen I. ;

Lindquist, Deborah ;

Chavarri-Guerra, Yanin ;

Aktan, Gursel ;

Rappold, Erica ;

Williams, Lisa S. ;

Finkelstein, Dianne M. .

LANCET ONCOLOGY, 2013, 14 (01) :88-96

[34] Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance [J].

Gu, Long ;

Waliany, Sarah ;

Kane, Susan E. .

PLOS ONE, 2009, 4 (07)

[35] Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial [J].

Guglin, Maya ;

Munster, Pamela ;

Fink, Angelina ;

Krischer, Jeffrey .

AMERICAN HEART JOURNAL, 2017, 188 :87-92

[36] HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer [J].

Harbeck, Nadia ;

Beckmann, Matthias W. ;

Rody, Achim ;

Schneeweiss, Andreas ;

Mueller, Volkmar ;

Fehm, Tanja ;

Marschner, Norbert ;

Gluz, Oleg ;

Schrader, Iris ;

Heinrich, Georg ;

Untch, Michael ;

Jackisch, Christian .

BREAST CARE, 2013, 8 (01) :49-55

[37] Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training [J].

Haykowsky, Mark J. ;

Mackey, John R. ;

Thompson, Richard B. ;

Jones, Lee W. ;

Paterson, D. Ian .

CLINICAL CANCER RESEARCH, 2009, 15 (15) :4963-4967

[38] Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial [J].

Huober, J. ;

Fasching, P. A. ;

Barsoum, M. ;

Petruzelka, L. ;

Wallwiener, D. ;

Thomssen, C. ;

Reimer, T. ;

Paepke, S. ;

Azim, H. A. ;

Ragosch, V. ;

Kubista, E. ;

Baumgaertner, A. K. ;

Beckmann, M. W. ;

May, C. ;

Nimmrich, I. ;

Harbeck, N. .

BREAST, 2012, 21 (01) :27-33

[39] Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J].

Hurvitz, Sara A. ;

Martin, Miguel ;

Symmans, W. Fraser ;

Jung, Kyung Hae ;

Huang, Chiun-Sheng ;

Thompson, Alastair M. ;

Harbeck, Nadia ;

Valero, Vicente ;

Stroyakovskiy, Daniil ;

Wildiers, Hans ;

Campone, Mario ;

Boileau, Jean-Francois ;

Beckmann, Matthias W. ;

Afenjar, Karen ;

Fresco, Rodrigo ;

Helms, Hans-Joachim ;

Xu, Jin ;

Lin, Yvonne G. ;

Sparano, Joseph ;

Slamon, Dennis .

LANCET ONCOLOGY, 2018, 19 (01) :115-126

[40] Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial [J].

Joensuu, Heikki ;

Fraser, Judith ;

Wildiers, Hans ;

Huovinen, Riikka ;

Auvinen, Paivi ;

Utriainen, Meri ;

Nyandoto, Paul ;

Villman, Kenneth K. ;

Halonen, Paivi ;

Granstam-Bjorneklett, Helena ;

Lundgren, Lotta ;

Sailas, Liisa ;

Turpeenniemi-Hujanen, Taina ;

Tanner, Minna ;

Yachnin, Jeffrey ;

Ritchie, Diana ;

Johansson, Oskar ;

Huttunen, Teppo ;

Neven, Patrick ;

Canney, Peter ;

Harvey, Vernon J. ;

Kellokumpu-Lehtinen, Pirkko-Liisa ;

Lindman, Henrik .

JAMA ONCOLOGY, 2018, 4 (09) :1199-1206

← 1 2 3 4 5 6 7 8 9 10 →